Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 2.42% and Operating profit at -39.23% over the last 5 years
2
Flat results in Mar 26
3
With ROE of 0.75%, it has a fair valuation with a 1.03 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,924 Million (Mid Cap)
137.00
NA
0.00%
0.01
0.75%
1.03
Revenue and Profits:
Net Sales:
631 Million
(Quarterly Results - Mar 2026)
Net Profit:
34 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.01%
0%
-11.01%
6 Months
-22.18%
0%
-22.18%
1 Year
-22.49%
0%
-22.49%
2 Years
-27.97%
0%
-27.97%
3 Years
-53.03%
0%
-53.03%
4 Years
-72.07%
0%
-72.07%
5 Years
-91.9%
0%
-91.9%
Shenzhen Kangtai Biological Products Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.42%
EBIT Growth (5y)
-39.23%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
1.71
Net Debt to Equity (avg)
0.19
Sales to Capital Employed (avg)
0.24
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
55.56%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.16%
ROE (avg)
6.62%
Valuation key factors
Factor
Value
P/E Ratio
137
Industry P/E
Price to Book Value
1.03
EV to EBIT
179.18
EV to EBITDA
26.99
EV to Capital Employed
1.03
EV to Sales
3.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.57%
ROE (Latest)
0.75%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bearish
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
631.10
609.60
3.53%
Operating Profit (PBDIT) excl Other Income
48.50
141.40
-65.70%
Interest
29.50
30.20
-2.32%
Exceptional Items
7.60
4.80
58.33%
Consolidate Net Profit
33.60
21.10
59.24%
Operating Profit Margin (Excl OI)
76.80%
58.40%
1.84%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 3.53% vs -9.20% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 59.24% vs 81.90% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,664.10
2,641.80
0.84%
Operating Profit (PBDIT) excl Other Income
468.30
468.70
-0.09%
Interest
119.50
124.50
-4.02%
Exceptional Items
27.80
1.40
1,885.71%
Consolidate Net Profit
70.30
201.60
-65.13%
Operating Profit Margin (Excl OI)
13.10%
43.60%
-3.05%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.84% vs -23.75% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -65.13% vs -76.59% in Dec 2024
About Shenzhen Kangtai Biological Products Co., Ltd. 
Shenzhen Kangtai Biological Products Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






